Exhibit 10.8 Collaboration Agreement Section 1: General Intention China Netcom of GuangXi Province ("Party A") and Beijing Candidsoft Technology Co. Ltd. ("Party B"), in accordance with People's Republic of China's Agreement Law and other regulations...Collaboration Agreement • August 6th, 2008 • China Voice Holding Corp.
ANDCollaboration Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Georgia
BETWEENCollaboration Agreement • June 5th, 2007 • Transition Therapeutics Inc. • New York
EXHIBIT 10.13 COLLABORATION AGREEMENTCollaboration Agreement • March 22nd, 2005 • BioNumerik Pharmaceuticals, Inc. • Services-commercial physical & biological research
COLLABORATION AGREEMENTCollaboration Agreement • August 31st, 2021 • Liverpool
EXHIBIT 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Collaboration Agreement • June 24th, 2004 • Viacell Inc • Services-commercial physical & biological research • New York
Dated _________________________201[] MODEL COLLABORATION AGREEMENT 1Collaboration Agreement • December 23rd, 2020
[The Technology Strategy Board has announced its intention to make a grant in respect of that project, subject to the terms of the offer letter referred to below, and subject to the parties entering into an agreement governing their collaboration.]
AMENDED AND RESTATED COLLABORATION AGREEMENTCollaboration Agreement • August 9th, 2019 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agreement”) is dated as of June 19, 2019 by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 2 Gansevoort Street, New York, NY 10014 (“CTI”), and TG Therapeutics, Inc. located at 2 Gansevoort Street, New York, NY 10014 (“TGTX”). CTI, on the one hand, and TGTX, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
COLLABORATION AGREEMENT Memorandum of Understanding Between: Open Food Web Foundation Ltd (“Open Food Foundation”) (hereinafter referred to as "Collaborator A" further referred to as "OFN ")Collaboration Agreement • January 8th, 2016
THIS AGREEMENT is made and is effective from this X day of September 2015, notwithstanding the signature date of this agreement.
Collaboration Agreement between Institute of Grassland and Environmental Research and Ceres, Inc.Collaboration Agreement • January 25th, 2012 • Ceres, Inc. • Agricultural production-crops • New York
THIS AGREEMENT is made this 1st day of April, 2007 (“Effective Date”), by and between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United States of America.
COLLABORATION AGREEMENT between PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBE INCORPORATED Dated as of June 15, 2010Collaboration Agreement • November 3rd, 2010 • Gen Probe Inc • Surgical & medical instruments & apparatus • California
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into between Pacific Biosciences of California, Inc., a Delaware corporation (“PacBio”), having a place of business at 1505 Adams Drive, Menlo Park, California 94025 and Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”), having a place of business at 10210 Genetic Center Drive, San Diego, California 92121. PacBio and Gen-Probe may each sometimes be referred to herein as a “party” and collectively as the “parties.”
COLLABORATION AGREEMENTCollaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 2, 2012 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and LIFE TECHNOLOGIES CORPORATION, a Delaware corporation having an address of 5791 Van Allen Way, Carlsbad, California 92008 (“Life Technologies”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • September 18th, 2006 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 24th day of February, 2006 (the “Effective Date”), by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having an office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”).
Fifth amendment to licensing, co-development and marketing agreement for Entereg (alvimopan)Collaboration Agreement • March 13th, 2021
THIS AMENDMENT NO. 5 TO COLLABORATION AGREEMENT (this “Amendment No. 5”), effective as of December 16, 2009 (the “Effective Date”), is made by and between ADOLOR CORPORATION, a Delaware corporation and having its principal office at 700 Pennsylvania Drive, Exton, Pennsylvania 19341 (“Adolor”), and GLAXO GROUP LIMITED, a United Kingdom corporation and having its principal office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). Adolor and GSK are each sometimes referred to individually as a “Party” and together as the “Parties.”
COLLABORATION AGREEMENTCollaboration Agreement • September 6th, 2021 • London
Collaboration Agreement between a patient advocate and a pharmaceutical companyCollaboration Agreement • November 18th, 2021
This is a reference agreement, specific for Collaboration Agreements, that should be adapted according to the needs of the users. It is based on the “Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies”, provided by the WECAN project on “Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies”, for the most recent version and more information about the guiding principles, please visit www.wecanadvocate.eu/rapp
Collaboration Agreement SummaryCollaboration Agreement • June 3rd, 2019
CONTRACTCollaboration Agreement • June 7th, 2019
NOW THEREFORE this Agreement witnesses that the parties mutually covenant and agree as follows: 3 PART 1Collaboration Agreement • July 3rd, 2000 • Graftech Inc • Electrical industrial apparatus • British Columbia
Collaboration Agreement SummaryCollaboration Agreement • July 28th, 2017
RM3804 TECHNOLOGY SERVICES 2 COLLABORATION AGREEMENT CONFIDENTIAL AND SUBJECT TO CONTRACTCollaboration Agreement • August 15th, 2017 • England and Wales
COLLABORATION AGREEMENT by and between VOYAGER THERAPEUTICS, INC. and GENZYME CORPORATION February 11, 2015Collaboration Agreement • November 6th, 2015 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of February 11, 2015 (the “Effective Date”), is entered into by and between Voyager Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Voyager”), and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
COLLABORATION AGREEMENTCollaboration Agreement • January 9th, 2020
This Collaboration Agreement (the “Agreement”) regulates the rights and obligations of the Parties in the project: (projectname, projectnumber) – hereafter referred to as the” Project”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Collaboration Agreement • September 8th, 2023 • CardieX LTD • Electromedical & electrotherapeutic apparatus
COLLABORATION AGREEMENTCollaboration Agreement • April 7th, 2021 • Idaho
This COLLABORATION AGREEMENT (the “Agreement”), dated as of July 1, 2021, is made by the Young Men’s Christian Association of Boise City, Idaho, DBA the Treasure Valley Family YMCA, an Idaho corporation (“YMCA”), and Joint School District No. 2, doing business as the West Ada School District, a body corporate and politic of the State of Idaho (“WASD”), provides as follows:
COLLABORATION AGREEMENTCollaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of August 17, 2011 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and CLARIENT DIAGNOSTIC SERVICES, INC., a Delaware corporation having an address of 31 Columbia, Aliso Viejo, California 92656 (“Clarient”).
COLLABORATION AGREEMENTCollaboration Agreement • May 11th, 2015 • Ignyta, Inc. • Pharmaceutical preparations • Delaware
This COLLABORATION AGREEMENT (the “Agreement”), effective as of November 3, 2006 (the “Effective Date”), is made by and between Ambit Biosciences Corporation a Delaware corporation, having a principal place of business at 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (“Ambit”), and Cephalon, Inc., a Delaware corporation, having a principal place of business at 41 Moores Road, Frazer, PA 19355 (“Cephalon”).
COLLABORATION AGREEMENTCollaboration Agreement • March 28th, 2013 • Ambit Biosciences Corp • Pharmaceutical preparations • California
This Collaboration Agreement (the “Agreement”) is entered into as of September 14, 2010 (the “Effective Date”) by and between AMBIT BIOSCIENCES CORPORATION, a Delaware corporation with its principal place of business located at 4215 Sorrento Valley Blvd., San Diego, California 92121 (“Ambit”), and GENOPTIX, INC., a Delaware corporation with its principal place of business located at 1811 Aston Avenue, Carlsbad, California 92008 (“Genoptix”). Ambit and Genoptix are also herein designated individually as “Party” and collectively as “Parties.”
EXHIBIT 10.14 COLLABORATION AGREEMENT This Collaboration Agreement (the "Agreement") is dated as of February 26, 1999 by and between EXELIXIS PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 260 Littlefield...Collaboration Agreement • April 7th, 2000 • Exelixis Inc • Services-commercial physical & biological research • Delaware
Collaboration AgreementCollaboration Agreement • May 31st, 2013
The effective date of this collaboration agreement (the “Collaboration Agreement”) is when there are at least 3 partners (see below and Article 9).
Collaboration AgreementCollaboration Agreement • July 17th, 2018
The GMC is located at the site of HMGU, headed by HMGU’s Institute of Experimental Genetics. The GMC is operated by its members HMGU, Technische Universität München (TUM), Ludwig-Maximilians-Universität München (LMU), Rheinische Friedrichs-Wilhelms- Universität Bonn (FWU), the University of Heidelberg (RKU) and the Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) and the Helmholtz-Zentrum für Infektionsforschung GmbH.
ARTICLE 1 - SCOPE OF COLLABORATION; COLLABORATION ACTIVITIESCollaboration Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Delaware
Collaboration AgreementCollaboration Agreement • February 14th, 2020 • Senmiao Technology LTD • Finance services
This Collaboration Agreement (hereinafter referred to as this “Agreement”) is made and entered into by and between the following parties in Haidian District, Beijing. This Agreement may be executed in paper form offline or in electronic form through the Didi Chuxing Online Contracting Platform (website: https://contract.didichuxing.com/, hereinafter referred to as the “Contracting Platform”). The Agreement executed offline in paper form shall become effective upon the completion of the execution by both Parties (hereinafter referred to as the “Effective Date”); and the Agreement executed online in electronic form shall become effective upon the completion of the execution on the Contracting Platform by both Parties (hereinafter referred to as the “Effective Date”) recorded by the third-party online document depository.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
COLLABORATION AGREEMENTCollaboration Agreement • April 23rd, 2020 • England and Wales
